Streetbeat News

Analyst Ratings

SXI

Analysts have provided mixed ratings for Standex International (NYSE:SXI) over the past quarter, with a majority being bullish. The average 12-month price target has increased slightly to $202.75. Key financial metrics show strong profitability and effective cost management, despite a recent revenue decline.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:01 pm

APA

The latest analyst ratings for APA (NASDAQ:APA) show a mix of bullish and bearish perspectives. Analysts have set a 12-month price target range of $30.00 to $52.00, with an average target of $38.00, reflecting a 7.79% decline from the prior average. Recent ratings include both upgrades and downgrades, indicating varied sentiment among analysts.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:01 pm

SLG

Analysts' ratings for SL Green Realty (NYSE:SLG) over the last quarter vary from bullish to bearish. The average 12-month price target has increased to $54.1, reflecting a 16.85% rise from the previous average. Analysts have recently raised their price targets, indicating a positive outlook despite the company's revenue challenges and below-industry-average ROE.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:00 pm

EHC

In the past three months, 7 analysts have provided ratings for Encompass Health (NYSE:EHC), ranging from bullish to bearish. The average 12-month price target has increased by 2.63% to $102.29. Analysts have made various adjustments to their ratings and price targets, reflecting their perceptions of the company's performance. Encompass Health has shown strong financial performance with significant revenue growth, high net margins, and efficient use of assets.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:00 pm

FANG

Diamondback Energy (NASDAQ:FANG) has been analyzed by 11 analysts over the last quarter, showing a range of ratings from bullish to bearish. The average 12-month price target is $215.91, with a high of $249.00 and a low of $154.00. Recent ratings show a trend towards more bullish sentiments. Financial metrics indicate strong performance with high revenue growth, net margin, ROE, and ROA, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 7:00 pm

ATNM

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma (AMEX:ATNM) but lowers the price target from $50 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:55 pm

AQMS

HC Wainwright & Co. analyst Amit Dayal maintains a Buy rating on Aqua Metals (NASDAQ:AQMS) but lowers the price target from $4 to $2.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:51 pm

TRUE

Needham analyst Chris Pierce maintains a Buy rating on TrueCar (NASDAQ:TRUE) but lowers the price target from $4 to $3.75.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:48 pm

TALK

Needham analyst Ryan MacDonald has reiterated a Hold rating on Talkspace (NASDAQ:TALK).

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:46 pm

TGTX

HC Wainwright & Co. has reiterated its Buy rating on TG Therapeutics (NASDAQ:TGTX) and maintained a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:45 pm